Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for a supplemental application to produce a new specification (0.1g) of the injectable drug Cytarabine, expanding its product line and enhancing market competitiveness [1][4]. Group 1: Drug Information - The drug approved is Cytarabine for injection, with a new specification of 0.1g, which is a chemical drug registered under the approval number H20269025 [1]. - Cytarabine is used for the induction and maintenance treatment of acute non-lymphocytic leukemia in adults and children, and it is effective against other types of leukemia as well [2]. - The company had previously obtained a registration certificate for the 0.5g specification of Cytarabine in March 2025, with a projected domestic market sales amount of approximately RMB 306 million for 2025 [2]. Group 2: R&D Investment - The company has invested approximately RMB 8.17 million in the research and development of the Cytarabine project to date [3]. Group 3: Impact on the Company - The approval of the 0.1g specification is considered equivalent to passing a consistency evaluation, which will enrich the company's product line and improve its market competitiveness [4].

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2026-008 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 注册分类：化学药品 申请人：浙江华海药业股份有限公司 浙江华海药业股份有限公司 关于获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的注射用阿糖胞苷的《药品补充申请批 准通知书》。该产品是在公司已获批的注射用阿糖胞苷（规格：0.5g）基础上，申 请新增规格 0.1g。现将相关情况公告如下： 一、药品的基本情况 药品名称：注射用阿糖胞苷 剂型：注射剂 规格：0.1g 申请事项：境内生产药品补充申请 药品批准文号：国药准字 H20269025 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品此 次申请事项符合药品注册的有关要求，批准本品增加 0.1g 规格 ...

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for a supplemental application for injectable Ara-C, adding a new specification of 0.1g to the already approved 0.5g version [1] Group 1 - The injectable Ara-C is used for the induction and maintenance treatment of acute non-lymphocytic leukemia in adults and children [1] - The product also has therapeutic effects on other types of leukemia, such as acute lymphocytic leukemia and chronic myeloid leukemia (blast crisis) [1] - The drug can be used alone or in combination with other antitumor agents, with better efficacy observed in combination therapy [1]

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for a supplemental application for injectable Ara-C, adding a new specification of 0.1g to the already approved 0.5g version [1] Group 1 - The newly approved injectable Ara-C is indicated for the induction and maintenance treatment of acute non-lymphocytic leukemia in adults and children [1] - The product also shows efficacy in treating other types of leukemia, such as acute lymphocytic leukemia and chronic myeloid leukemia (blast crisis) [1] - Injectable Ara-C can be used alone or in combination with other antitumor drugs, with improved efficacy observed in combination therapy [1]

证券研究报告 | 行业简评报告 2026 年 02 月 03 日 布局消费反转！ 大消费组二月消费金股 研究部/消费品 % 1m 6m 12m 绝对表现 4.3 4.6 25.0 相对表现 3.1 -8.7 1.7 资料来源：公司数据、招商证券 -10 0 10 20 30 Feb/25 May/25 Sep/25 Jan/26 (%) 消费品 沪深300 相关报告 1、《招商证券 1 月港股消费观察： 外卖反垄断如何影响港股消费股前 景？》2026-01-27 2、《大消费组一月消费金股—双节 消费亮点前瞻》2026-01-06 ❑ 轻纺 杨蕊菁：看好家居板块修复以及倍加洁益生菌业务发展 风险提示：消费下行风险，消费复苏疲软风险、宏观经济变动风险等。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 1216 | 23.5 | | 总市值（十亿元） | 17628.3 | 15.6 | | 流通市值（十亿元） | 16321.4 | 15.9 | 行业指数 3、《招商证券 12 月港股消费观察— 1-2 月流动性改善后港股消费买什 么？》2025 ...

Core Insights - The Chinese generic drug industry is undergoing significant changes due to policy factors, including the implementation of the drug marketing authorization holder system and early resolution mechanisms for patent disputes, which are reshaping the competitive landscape [1][11]. Industry Overview - The number of generic drug products that have passed or are deemed to have passed evaluations in China reached 2,998 in 2024, an increase of 1,008 from 2023, representing a year-on-year growth of 50.65% [1][11]. - The proportion of contract manufacturing among these evaluated generic drug products reached 33% in 2024, up from 12% in 2020, indicating a trend towards deeper industry collaboration and resource allocation [1][11]. Generic Drug Consistency Evaluation - The consistency evaluation of generic drugs ensures that they meet the same quality and efficacy standards as original drugs, which is crucial for patient safety and effective treatment [2][3]. - The evaluation process includes determining reference formulations, conducting pharmaceutical research, and ongoing monitoring to ensure compliance with quality and safety standards [2][3]. Industry Policies - Recent policies have been introduced to enhance the quality of generic drugs and promote their market acceptance, including the 2025 guidelines for deepening drug regulation reforms [5][6]. - The establishment of a reference formulation directory is essential for conducting consistency evaluations, with 87 batches published by the National Medical Products Administration by the end of 2024 [9]. Market Dynamics - The market for chemical generic drugs in China is projected to be 868.3 billion yuan in 2024, showing a decline of 3% year-on-year, with the market share of chemical generics in the overall drug market decreasing from 60% in 2018 to 50% in 2024 [7][8]. - The competitive landscape is becoming increasingly polarized, with leading pharmaceutical companies gaining significant market share while smaller firms face challenges due to funding and research limitations [11]. Key Companies - Notable companies in the generic drug consistency evaluation sector include Tigermed Pharmaceutical Technology Co., Ltd., Huahai Pharmaceutical Co., Ltd., and Hengrui Medicine Co., Ltd., among others [1][11]. - Tigermed reported a revenue of 1.71 billion yuan in clinical trial services for the first half of 2025, reflecting a 3.07% increase year-on-year, while Hengrui Medicine achieved a revenue of 13.693 billion yuan, up 12.85% [12][14]. Future Trends - The focus of generic drug evaluations is expected to shift towards high-tech barrier products, such as controlled-release formulations and complex injectables, requiring enhanced reverse engineering and pharmaceutical research capabilities [15][16]. - The production model is transitioning from batch production to continuous manufacturing, which aims to ensure consistent quality and compliance with evaluation standards [15][16]. - Companies are encouraged to adopt a full lifecycle management approach for their products, emphasizing ongoing research and optimization post-evaluation to maintain market leadership [16].

Core Viewpoint - The healthcare index (980016) closed at 6173.05 points, down 0.98%, with a trading volume of 32.835 billion yuan and a turnover rate of 1.29% [1] Group 1: Index Performance - Among the index constituents, 11 stocks rose while 39 stocks fell, with Sangfor Technologies leading the gainers at a 10.93% increase and Huahai Pharmaceutical leading the decliners with a 3.79% drop [1] - The top ten constituents of the healthcare index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 10.23%, 9.85%, and 8.23% [1] Group 2: Market Capitalization and Price Movements - WuXi AppTec has a market capitalization of 285.814 billion yuan, while Hengrui Medicine and Mindray Medical have market capitalizations of 379.648 billion yuan and 232.983 billion yuan, respectively [1] - The latest prices for the top ten constituents range from 11.12 yuan for Aier Eye Hospital to 192.16 yuan for Mindray Medical, with varying price changes [1] Group 3: Capital Flow - The net outflow of main funds from the healthcare index constituents totaled 1.252 billion yuan, while retail investors saw a net inflow of 1.093 billion yuan [1] - Detailed capital flow data indicates that Junshi Biosciences experienced a net inflow of 1.93 million yuan from main funds, while other companies like Dong'e Ejiao and Tigermed saw mixed capital flows [2]

Core Viewpoint - The report highlights the significant growth driven by technology in certain sectors, while also noting the substantial losses due to cyclical downturns in others [1] Performance Growth Highlights - **Zhongwei Company (688012)**: Expected net profit between 208 million to 218 million yuan, a year-on-year increase of 28.74% to 34.93%, driven by increased recognition of plasma etching equipment and a surge in market demand [5] - **Lianchuang Optoelectronics (600363)**: Expected net profit between 43.5 million to 53.2 million yuan, a year-on-year increase of 80.36% to 120.57%, attributed to significant growth in laser business and improved profitability in traditional sectors [6] - **Ruixin Microelectronics (603893)**: Expected net profit between 102.3 million to 110.3 million yuan, a year-on-year increase of 71.97% to 85.42%, driven by rapid growth in the AIoT market and recognition of new AI technology [7] - **Sangfor Health (688336)**: Expected net profit around 290 million yuan, a year-on-year increase of approximately 311.35%, due to a significant collaboration with Pfizer and advancements in clinical research [8] - **Pulite (002324)**: Expected net profit growth of 155.76% to 194.73%, driven by the demand for high polymer materials in the automotive lightweight trend [9] - **Tonghua Dongbao (600867)**: Expected net profit around 124.21 million yuan, turning from loss to profit, driven by market share gains in insulin products [10] - **Suotong Development (603612)**: Expected net profit between 73 million to 85 million yuan, a year-on-year increase of 167.98% to 212.03%, due to rising prices and demand in the prebaked anode industry [11] Major Performance Declines - **China Shipbuilding Technology (600072)**: Expected net loss between -260 million to -340 million yuan, a year-on-year decline of over 24 times, due to cyclical downturns in shipbuilding and high material costs [12] - **Silver Nonferrous Metals (601212)**: Expected net loss between -45 million to -67.5 million yuan, transitioning from profit to loss due to legal disputes affecting financial performance [13] - **China Metallurgical Group (601618)**: Expected net profit between 130 million to 160 million yuan, a year-on-year decline of 76.28% to 80.73%, impacted by the downturn in the construction industry [14] - **Jindi Group (600383)**: Expected net loss between -1.11 billion to -1.35 billion yuan, with increased losses due to declining sales and inventory impairments [15] - **Jianfa Co. (600153)**: Expected net loss between -1 billion to -520 million yuan, transitioning from profit to loss due to increased impairments in real estate [16] Industry Trend Analysis - **Technology and Innovation-Driven Sectors**: Companies in semiconductor equipment, laser military applications, and innovative pharmaceuticals are experiencing rapid growth due to high demand in AIoT, national defense, and biomedicine [23] - **Traditional Cyclical Industries**: Sectors like coal and engineering machinery are facing significant adjustments due to demand shortages and price declines, leading to widespread performance pressures [24] - **Pharmaceutical Industry Disparities**: Innovative drugs are seeing explosive growth through external licensing, while traditional formulations and raw materials are significantly impacted by procurement policies [24] - **External Environment Uncertainties**: Factors such as international trade tensions and regulatory changes are significantly affecting corporate performance, necessitating enhanced risk management [24] - **Asset Quality Risks**: Many companies are reporting substantial asset impairment provisions, indicating potential inefficiencies in previous investments [24]

Group 1 - Huahai Pharmaceutical's stock price dropped by 5.19% to 16.25 CNY per share, with a trading volume of 266 million CNY and a turnover rate of 1.07%, resulting in a total market capitalization of 24.33 billion CNY [1] - The company, established on February 28, 2001, and listed on March 4, 2003, specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty APIs [1] - The revenue composition of Huahai Pharmaceutical includes finished drug sales at 61.86%, API and intermediate sales at 36.75%, other sales at 0.78%, and technical services at 0.62% [1] Group 2 - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Huahai Pharmaceutical, having reduced its holdings by 250,100 shares to 13.1675 million shares, representing 0.88% of the circulating shares [2] - The estimated floating loss for the Southern CSI 500 ETF today is approximately 11.72 million CNY [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 144.69 billion CNY, achieving a year-to-date return of 13.99% and a one-year return of 53.16% [2]

Summary of Key Points from Conference Call Records Industry Overview - The pharmaceutical industry is experiencing mixed performance in the A-share market, with the Shanghai Composite Index closing at 4132.61 points, down 0.09%, and the Shenzhen Component Index at 14316.64 points, down 0.85% [1][1] - The Shenwan Pharmaceutical Industry Index closed at 8648.35 points, up 0.29%, while the Hang Seng Healthcare Index in Hong Kong closed at 4032.36 points, down 1.58% [1][1] Company-Specific Insights Performance Forecasts - **Guangji Pharmaceutical**: Expected net loss for 2025 is between 518 million to 399 million yuan, a significant increase from the previous year's loss of 295 million yuan [2][2] - **Yixin Pharmacy**: Projected net profit for 2025 is between 260 million to 330 million yuan, a substantial increase of 127.79% to 189.12% year-on-year [2][3] - **International Medicine**: Anticipated revenue drop to 4.06 billion to 4.08 billion yuan, a 15.7% decline, with net loss expected to widen to between 315 million to 295 million yuan [3][3] - **Weichip Bio**: Expected revenue of 910 million yuan, a 38.32% increase, with net profit turning positive at 53.46 million yuan, a significant improvement from a loss of 115 million yuan [3][3] - **Tonghua Dongbao**: Forecasted net profit of 1.242 billion yuan, recovering from a loss of 42.72 million yuan in the previous year [4][4] - **Meinuo Pharma**: Expected net profit between 100 million to 123 million yuan, a growth of 49.69% to 84.11% year-on-year [4][4] - **Sangfor Biopharma**: Projected revenue of 4.2 billion yuan, a significant increase of 251.76%, with net profit expected to reach 2.9 billion yuan, a 311.35% increase [4][5] - **Huahai Pharmaceutical**: Expected net profit to decline by 70% to 80%, with projections between 224 million to 335 million yuan [5][5] - **Dabo Medical**: Anticipated net profit between 580 million to 610 million yuan, a growth of 62.55% to 70.96% [5][5] Regulatory Approvals - **Hengrui Medicine**: Received clinical trial approval for SHR-1049 injection [2][2] - **Qianjin Pharmaceutical**: Obtained drug registration for aluminum magnesium carbonate chewable tablets [2][2] - **Wantai Bio**: Two-valent HPV vaccine passed WHO PQ periodic review [2][2] Market Trends - The A-share market shows volatility with significant fluctuations in stock performance, particularly in the pharmaceutical sector, indicating potential investment opportunities and risks [1][1] - The performance of individual companies varies widely, with some showing strong growth while others face significant losses, highlighting the need for careful analysis when considering investments in this sector [2][3][4][5]